These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Blood pressure and disability-free survival among community-dwelling diabetic and non-diabetic elderly patients receiving antihypertensive treatment. Higashikawa T; Hamazaki Y; Iritani O; Morita T; Himeno T; Okuno T; Yano H; Watanabe K; Okuro M; Kanda T; Morimoto S Geriatr Gerontol Int; 2016 Mar; 16(3):365-73. PubMed ID: 25870013 [TBL] [Abstract][Full Text] [Related]
44. The impact of SPRINT on the future treatment of hypertension: a mini review. Chrysant SG Drugs Today (Barc); 2016 Mar; 52(3):193-8. PubMed ID: 27186593 [TBL] [Abstract][Full Text] [Related]
45. Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results. Huang C; Dhruva SS; Coppi AC; Warner F; Li SX; Lin H; Nasir K; Krumholz HM J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29133522 [TBL] [Abstract][Full Text] [Related]
46. [Control of blood pressure in diabetic patients in primary care setting. DIAPA study]. García Vallejo O; Vicente Lozano J; Vegazo O; Jiménez Jiménez FJ; Llisterri Caro JL; Redón J; Med Clin (Barc); 2003 Apr; 120(14):529-34. PubMed ID: 12724064 [TBL] [Abstract][Full Text] [Related]
47. Ambulatory Blood Pressure Monitoring (ABPM) as the reference standard for diagnosis of hypertension and assessment of vascular risk in adults. Hermida RC; Smolensky MH; Ayala DE; Portaluppi F Chronobiol Int; 2015; 32(10):1329-42. PubMed ID: 26587588 [TBL] [Abstract][Full Text] [Related]
48. Blood Pressure Management in Patients with Type 2 Diabetes. Eguchi K Intern Med; 2015; 54(18):2285-9. PubMed ID: 26370850 [TBL] [Abstract][Full Text] [Related]
49. Implications of the New 2017 American College of Cardiology/American Heart Association Guidelines for Hypertension. Aronow WS Minerva Cardioangiol; 2019 Oct; 67(5):399-410. PubMed ID: 31220914 [TBL] [Abstract][Full Text] [Related]
51. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials. Thomopoulos C; Parati G; Zanchetti A J Hypertens; 2014 Dec; 32(12):2296-304. PubMed ID: 25259547 [TBL] [Abstract][Full Text] [Related]
52. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. Tillin T; Orchard T; Malm A; Fuller J; Chaturvedi N J Hypertens; 2011 Jul; 29(7):1457-62. PubMed ID: 21602709 [TBL] [Abstract][Full Text] [Related]
53. Difficulties in reaching therapeutic goals for hypertension and dysplipidaemia in patients with type 2 diabetes in general practice. Knudsen ST; Mosbech TH; Hansen B; Kønig E; Johnsen PC; Kamper AL Dan Med J; 2013 Dec; 60(12):A4740. PubMed ID: 24355449 [TBL] [Abstract][Full Text] [Related]
54. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Fleg JL; Evans GW; Margolis KL; Barzilay J; Basile JN; Bigger JT; Cutler JA; Grimm R; Pedley C; Peterson K; Pop-Busui R; Sperl-Hillen J; Cushman WC Hypertension; 2016 Oct; 68(4):888-95. PubMed ID: 27504006 [TBL] [Abstract][Full Text] [Related]
55. Evaluating the treatment of hypertension in diabetes mellitus: a need for better control? Sequeira RP; Al Khaja KA; Damanhori AH J Eval Clin Pract; 2004 Feb; 10(1):107-16. PubMed ID: 14731158 [TBL] [Abstract][Full Text] [Related]
56. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Zhang Y; Zhang X; Liu L; Zanchetti A; Eur Heart J; 2011 Jun; 32(12):1500-8. PubMed ID: 21345850 [TBL] [Abstract][Full Text] [Related]
57. Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus. Supina AL; Guirguis LM; Majumdar SR; Lewanczuk RZ; Lee TK; Toth EL; Johnson JA Clin Ther; 2004 Apr; 26(4):598-606. PubMed ID: 15189757 [TBL] [Abstract][Full Text] [Related]
58. How We Got Where We Are in Blood Pressure Targets. Herberth J; Soliman KM; Fülöp T; Basile JN Curr Hypertens Rep; 2021 Jun; 23(6):33. PubMed ID: 34110518 [TBL] [Abstract][Full Text] [Related]
59. Risk of developing type 2 diabetes according to blood pressure levels and presence or absence of hypertensive treatment: the Saku study. Tatsumi Y; Morimoto A; Asayama K; Sonoda N; Miyamatsu N; Ohno Y; Miyamoto Y; Izawa S; Ohkubo T Hypertens Res; 2019 Jan; 42(1):105-113. PubMed ID: 30393378 [TBL] [Abstract][Full Text] [Related]
60. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]